Author

M. Yazdanifar

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Organism:human· 2

Frequent Co-Authors

M. Bose· 2 shared P. Grover· 2 shared P. Mukherjee· 2 shared R. Zhou· 2 shared S.-t. Wu· 2 shared A. J. Sanders· 1 shared A. W. Truman· 1 shared C. Brouwer· 1 shared

Activity by Year

2019-2020 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 39 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

M. Bose

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintApr 29, 2020

Tumor -Associated MUC1 Regulates TGF-β Signaling and Function in Pancreatic Ductal Adenocarcinoma

P. Grover, S. Nath, M. Bose…·P. Mukherjee

This study shows that high tMUC1 expression in PDA correlates with altered TGF-β signaling, promoting tumor growth and resistance to TGF-β therapy.

DOI 10.1101/2020.04.29.068577

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologyCellsPeer-reviewedSep 11, 2019

Overcoming Immunological Resistance Enhances the Efficacy of a Novel anti-tMUC1 CAR T Cell Treatment Against Pancreatic Ductal Adenocarcinoma

M. Yazdanifar, R. Zhou, P. Grover…·P. Mukherjee

This study develops a novel tMUC1-targeting CAR T cell therapy for pancreatic ductal adenocarcinoma and shows that combining it with inhibitors of IDO1, COX1/2, and Gal-9 enhances its efficacy against resistant tumors.

DOI 10.3390/cells8091070

humanbulk RNA-seq

𝕏 PostBluesky